TRV GP V, LLC

BOSTON, MA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$475.0M2026 Q3
Positions4
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.100.0%

TRV GP V, LLC reported 4 positions worth $475.0M as of September 30, 2026 (13F filed November 16, 2026). Largest holding: SEPN (50.0%). Biggest move: reduce SEPN ($5.8M).

4 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 SEPNSepterna$237.5M49.99%6,068,391——+6.5%
▸ 2 RAPPRapport Therapeutics$211.0M44.43%6,280,525——-26.1%
▸ 3 MAZEMaze Therapeutics$25.8M5.44%950,800——+24.7%
▸ 4 LSTALisata Therapeutics$655.5K0.14%455,192———

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does TRV GP V, LLC hold as of Q3 2026?

TRV GP V, LLC reported 4 positions worth $475.0M in its Q3 2026 13F filing. Largest positions: SEPN (50.0%), RAPP (44.4%), MAZE (5.4%) and LSTA (0.1%).

What did TRV GP V, LLC buy in Q3 2026?

New positions: LSTA.

What did TRV GP V, LLC sell in Q3 2026?

Reduced: SEPN.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.